Pectin in cancer therapy: A review

Trends in Food Science and Technology

Volumn 44, Issue 2, 2015, Pages 258-271

  Zhang, Wenbo ^a   Xu, Ping ^a   Zhang, Han ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CELL DEATH; FUNCTIONAL GROUPS; AMPHIBIOUS VEHICLES;

ANTI-CANCER DRUG DELIVERY; ANTI-TUMOR ACTIVITIES; ANTITUMOR MECHANISMS; IMMUNOLOGICAL RESPONSE; LOW MOLECULAR MASS; PHYSICOCHEMICAL PROPERTY; PLANT POLYSACCHARIDES; STRUCTURE ACTIVITY RELATIONSHIPS;

DISEASES;

EID: 84937162645     PISSN: 09242244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tifs.2015.04.001     Document Type: Review

References (142)

1. Almeida E.A., Facchi S.P., Martins A.F., Nocchi S., Schuquel I.T., Nakamura C.V., et al. Synthesis and characterization of pectin derivative with antitumor property against Caco-2 colon cancer cells. Carbohydrate Polymers 2015, 115:139-145.
2. Attari F., Sepehri H., Delphi L., Goliaei B. Apoptotic and necrotic effects of pectic acid on rat pituitary GH3/B6 tumor cells. Iranian Biomedical Journal 2009, 13(4):229-236.
3. Avivi-Green C., Polak-Charcon S., Madar Z., Schwartz B. Apoptosis cascade proteins are regulated invivo by high intracolonic butyrate concentration: correlation with colon cancer inhibition. Oncology Research 2000, 12(2):83-95.
4. Avivi-Green C., Polak-Charcon S., Madar Z., Schwartz B. Dietary regulation and localization of apoptosis cascade proteins in the colonic crypt. Journal of Cellular Biochemistry 2000, 77(1):18-29.
5. Azémar M., Hildenbrand B., Haering B., Heim M.E., Unger C. Clinical benefit in patients with advanced solid tumors treated with modified citrus Pectin: a prospective pilot study. Clinical Medicine: Oncology 2007, 1:73-80.
6. Bergman M., Djaldetti D., Salman H., Bessler H. Effect of citrus pectin on malignant cell proliferation. Biomedicine & Pharmacotherapy 2010, 64(1):44-47.
7. Brown G.D., Taylor P.R., Reid D.M., Willment J.A., Williams D.L., Martinez-Pomares L., et al. Dectin-1 is a major beta-glucan receptor on macrophages. Journal of Experimental Medicine 2002, 196(3):407-412.
8. Caffall K.H., Mohnen D. The structure, function, and biosynthesis of plant cell wall pectic polysaccharides. Carbohydrate Research 2009, 344(14):1879-1900.
9. Chauhan D., Li G., Podar K., Hideshima T., Neri P., He D., et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Research 2005, 65(18):8350-8358.
10. Cheng H., Li S., Fan Y., Gao X., Hao M., Wang J., et al. Comparative studies of the antiproliferative effects of ginseng polysaccharides on HT-29 human colon cancer cells. Medical Oncology 2011, 28(1):175-181.
11. Cheng H., Zhang Z., Leng J., Liu D., Hao M., Gao X., et al. The inhibitory effects and mechanisms of rhamnogalacturonan I pectin from potato on HT-29 colon cancer cell proliferation and cell cycle progression. International Journal of Food Science & Nutrition 2013, 64(1):36-43.
12. Chen C.H., Sheu M.T., Chen T.F., Wang Y.C., Hou W.C., Liu D.Z., et al. Suppression of endotoxin-induced proinflammatory responses by citrus pectin through blocking LPS signaling pathways. Biochemical Pharmacology 2006, 72(8):1001-1009.
13. Choi H.S., Kim K.H., Sohn E., Park J.D., Kim B.O., Moon E.Y., et al. Red ginseng acidic polysaccharide (RGAP) in combination with IFN-gamma results in enhanced macrophage function through activation of the NF-kappaB pathway. Bioscience Biotechnology & Biochemistry 2008, 72(7):1817-1825.
14. Cho Y., Turner N.D., Davidson L.A., Chapkin R.S., Carroll R.J., Lupton J.R. A chemoprotective fish oil/pectin diet enhances apoptosis via Bcl-2 promoter methylation in rat azoxymethane-induced carcinomas. Experimental Biology & Medicine (Maywood, N.J.) 2012, 237(12):1387-1393.
15. Cobs-Rosas M., Concha-Olmos J., Weinstein-Oppenheimer C., Zúñiga-Hansen M.E. Assessment of antiproliferative activity of pectic substances obtained by different extraction methods from rapeseed cake on cancer cell lines. Carbohydrate Polymers 2015, 117:923-932.
16. Courts F.L. Profiling of modified citrus pectin oligosaccharide transport across Caco-2 cell monolayers. PharmaNutrition 2013, 1(1):22-31.
17. Dange M.C., Srinivasan N., More S.K., Bane S.M., Upadhya A., Ingle A.D., et al. Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells. Clinical & Experimental Metastasis 2014, 31(6):661-673.
18. Demotte N., Wieërs G., van der Smissen P., Moser M., Schmidt C., Thielemans K., et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Research 2010, 70(19):7476-7488.
19. Dennis J.W., Lau K.S., Demetriou M., Nabi I.R. Adaptive regulation at the cell surface by N-glycosylation. Traffic 2009, 10(11):1569-1578.
20. Dev R.K., Bali V., Pathak K. Novel microbially triggeredcolon specific delivery system of 5-fluorouracil: statistical optimization, invitro, invivo, cytotoxic and stability assessment. International Journal of Pharmaceutics 2011, 411(1-2):142-151.
21. Dudas S.P., Yunker C.K., Sternberg L.R., Byrd J.C., Bresalier R.S. Expression of human intestinal mucin is modulated by the beta-galactoside binding protein galectin-3 in colon cancer. Gastroenterology 2002, 123(3):817-826.
22. Eliaz I., Hotchkiss A.T., Fishman M.L., Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytotherapy Research 2006, 20(10):859-864.
23. Fan Y., Cheng H., Liu D., Zhang X., Wang B., Sun L., et al. The inhibitory effect of ginseng pectin on L-929 cell migration. Archives of Pharmacal Research 2010, 33(5):681-689.
24. Flint H.J., Bayer E.A., Rincon M.T., Lamed R., White B.A. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nature Reviews Microbiology 2008, 6(2):121-131.
25. Fowler M., Thomas R.J., Atherton J., Roberts I.S., High N.J. Galectin-3 binds to Helicobacter pylori O-antigen: it is upregulated and rapidly secreted by gastric epithelial cells in response to H. pylori adhesion. Cellular Microbiology 2006, 8(1):44-54.
26. Fukumori T., Kanayama H.O., Raz A. The role of galectin-3 in cancer drug resistance. Drug Resistance Updates 2007, 10(3):101-108.
27. Gao X., Liu D., Fan Y., Li X., Xue H., Ma Y., et al. The two endocytic pathways mediated by the carbohydrate recognition domain and regulated by the collagen-like domain of galectin-3 in vascular endothelial cells. PLoS One 2012, 7(12):e52430.
28. Gao X., Zhi Y., Sun L., Peng X., Zhang T., Xue H., et al. The inhibitory effects of a rhamnogalacturonan I (RG-I) domain from ginseng pectin on galectin-3 and its structure-activity relationship. Journal of Biological Chemistry 2013, 288(47):33953-33965.
29. Gao X., Zhi Y., Zhang T., Xue H., Wang X., Foday A.D., et al. Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3. Glycoconjugate Journal 2012, 29(4):159-165.
30. Garthoff J.A., Heemskerk S., Hempenius R.A., Lina B.A., Krul C.A., Koeman J.H., et al. Safety evaluation of pectin-derived acidic oligosaccharides (pAOS): genotoxicity and sub-chronic studies. Regulatory Toxicology & Pharmacology 2010, 57(1):31-42.
31. Georgiev Y., Ognyanov M., Yanakieva I., Kussovski V., Kratchanova M. Isolation, characterization and modification of citrus pectins. Journal of Bioscience & Bioengineering 2012, 1(3):223-233.
32. Glinskii O.V., Huxley V.H., Glinsky G.V., Pienta K.J., Raz A., Glinsky V.V. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 2005, 7(5):522-527.
33. Glinsky V.V., Huflejt M.E., Glinsky G.V., Deutscher S.L., Quinn T.P. Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Research 2000, 60(10):2584-2588.
34. Glinsky V.V., Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydrate Research 2009, 344(14):1788-1791.
35. Gómez B., Gullón B., Remoroza C., Schols H.A., Parajó J.C., Alonso J.L. Purification, characterization, and prebiotic properties of pectic oligosaccharides from orange peel wastes. Journal of Agricultural and Food Chemistry 2014, 62(40):9769-9782.
36. Guess B.W., Scholz M.C., Strum S.B., Lam R.Y., Johnson H.J., Jennrich R.I. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer & Prostatic Diseases 2003, 6(4):301-304.
37. Guha P., Kaptan E., Bandyopadhyaya G., Kaczanowska S., Davila E., Thompson K., et al. Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proceedings of the National Academy of Sciences, U S A 2013, 110(13):5052-5057.
38. Gunning A.P., Bongaerts R.J., Morris V.J. Recognition of galactan components of pectin by galectin-3. FASEB Journal 2009, 23(2):415-424.
39. Gunning A.P., Pin C., Morris V.J. Galectin 3-β-galactobiose interactions. Carbohydrate Polymers 2013, 92(1):529-533.
40. Hao M., Yuan X., Cheng H., Xue H., Zhang T., Zhou Y., et al. Comparative studies on the anti-tumor activities of high temperature- and pH-modified citrus pectins. Food & Function 2013, 4(6):960-971.
41. Harazono Y., Nakajima K., Raz A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer & Metastasis Reviews 2014, 33(1):285-294.
42. Hayashi A., Gillen A.C., Lott J.R. Effects of daily oral administration of quercetin chalcone and modified citrus pectin on implanted colon-25 tumor growth in Balb-c mice. Alternative Medicine Review 2000, 5(6):546-552.
43. He W., Du Q., Cao D.Y., Xiang B., Fan L.F. Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. International Journal of Pharmaceutics 2008, 348(1-2):35-45.
44. Heitman D.W., Hardman W.E., Cameron I.L. Dietary supplementation with pectin and guar gum on 1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Carcinogenesis 1992, 13(5):815-818.
45. Hensel A., Meier K. Pectins and xyloglucans exhibit antimutagenic activities against nitroaromatic compounds. Planta Medica 1999, 65(5):395-399.
46. Heusschen R., Griffioen A.W., Thijssen V.L. Galectin-9 in tumor biology: a jack of multiple trades. Biochimica et Biophysica Acta 2013, 1836(1):177-185.
47. Hinz S.W., Verhoef R., Schols H.A., Vincken J.P., Voragen A.G. Type I arabinogalactan contains β-D-Galp-(1-->3)-β-D-Galp structural elements. Carbohydrate Research 2005, 340(13):2135-2143.
48. Hossein G., Keshavarz M., Ahmadi S., Naderi N. Synergistic effects of PectaSol-c modified citrus pectin an inhibitor of Galectin-3 and Paclitaxel on apoptosis of human SKOV-3 Ovarian Cancer cells. Asian Pacific Journal of Cancer Prevention 2013, 14(12):7561-7568.
49. Hsieh T., Wu J.M. Changes in cell growth, cyclin/kinase, endogenous phosphoproteins and nm23 gene expression in human prostatic JCA-1 cells treated with modified citrus pectin. Biochemistry & Molecular Biology International 1995, 37(5):833-841.
50. Inohara H., Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconjugate Journal 1994, 11(6):527-532.
51. Iurisci I., Tinari N., Natoli C., Angelucci D., Cianchetti E., Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clinical Cancer Research 2000, 6(4):1389-1393.
52. Jackson C.L., Dreaden T.M., Theobald L.K., Tran N.M., Beal T.L., Eid M., et al. Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure. Glycobiology 2007, 17(8):805-819.
53. Jacobasch G., Dongowski G., Florian S., Müller-Schmehl K., Raab B., Schmiedl D. Pectin does not inhibit intestinal carcinogenesis in APC-deficient Min/+ mice. Journal of Agricultural and Food Chemistry 2008, 56(4):1501-1510.
54. Jacobs L.R., Lupton J.R. Relationship between colonic luminal pH, cell proliferation and colon carcinogenesis in 1,2-dimethylhydrazine treated rats fed high fiber diets. Cancer Research 1986, 46(4 Pt 1):1727-1734.
55. Jeon C., Kang S., Park S., Lim K., Hwang K.W., Min H. T cell stimulatory effects of Korean red ginseng through modulation of myeloid-derived suppressor cells. Journal of Ginseng Research 2011, 35(4):462-470.
56. Jia X. The use of natural anti-Rhamnose antibody to enhance recognization and killing of tumor cells 2010, M.S. thesis, Shandong University, Jinan.
57. Jiang J., Eliaz I., Sliva D. Synergistic and additive effects of modified citrus Pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells. Integrative Cancer Therapies 2013, 12(2):145-152.
58. Johnson K.D., Glinskii O.V., Mossine V.V., Turk J.R., Mawhinney T.P., Anthony D.C., et al. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 2007, 9(8):662-670.
59. Kang H.J., Jo C., Kwon J.H., Son J.H., An B.J., Byun M.W. Antioxidant and cancer cell proliferation inhibition effect of citrus pectin-oligosaccharide prepared by irradiation. Journal of Medicinal Food 2006, 9(3):313-320.
60. Katav T., Liu L., Traitel T., Goldbart R., Wolfson M., Kost J. Modified pectin-based carrier for gene delivery: cellular barriers in gene delivery course. Journal of Controlled Release 2008, 130(2):183-191.
61. Katzenmaier E.M., André S., Kopitz J., Gabius H.J. Impact of sodium butyrate on the network of adhesion/growth-regulatory galectins in human colon cancer. invitro. Anticancer Research 2014, 34(10):5429-5438.
62. Kim H.R., Lin H.M., Biliran H., Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Research 1999, 59(16):4148-4154.
63. Klyosov A. Galectin-targeted drug design. Glycobiology & drug design. ACS symposium series 2012, 25-66. American Chemical Society, Washington, DC. A. Klyosov (Ed.).
64. Kolatsi-Joannou M., Price K.L., Winyard P.J., Long D.A. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One 2011, 6(4):e18683.
65. Krall S.M., McFeeters R.F. Pectin hydrolysis: effect of temperature, degree of methylation, pH, and calcium on hydrolysis rates. Journal of Agricultural & Food Chemistry 1998, 46(4):1311-1315.
66. Laguinge L.M., Samara R.N., Wang W., El-Deiry W.S., Corner G., Augenlicht L., et al. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Research 2008, 68(3):909-917.
67. Leclere L., Cutsem P.V., Michiels C. Anti-cancer activities of pH- or heat-modified pectin. Frontiers in Pharmacology 2013, 4(128):1-8. eCollection.
68. Lee Y.K., Lin T.H., Chang C.F., Lo Y.L. Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma. PLoS One 2013, 8(11):e82478.
69. Lee E.H., Park H.R., Shin M.S., Cho S.Y., Choi H.J., Shin K.S. Antitumor metastasis activity of pectic polysaccharide purified from the peels of Korean citrus Hallabong. Carbohydrate Polymers 2014, 111:72-79.
70. Lee J.H., Shim J.S., Lee J.S., Kim M.K., Chung M.S., Kim K.H. Pectin-like acidic polysaccharide from Panax ginseng with selective antiadhesive activity against pathogenic bacteria. Carbohydrate Research 2006, 341(9):1154-1163.
71. Lee J.H., Shim J.S., Lee J.S., Kim J.K., Yang I.S., Chung M.S., et al. Inhibition of pathogenic bacterial adhesion by acidic polysaccharide from green tea (Camellia sinensis). Journal of Agricultural & Food Chemistry 2006, 54(23):8717-8723.
72. Lepur A., Salomonsson E., Nilsson U.J., Leffler H. Ligand induced galectin-3 protein self-association. Journal of Biological Chemistry 2012, 287(26):21751-21756.
73. Liu Y., Ahmad H., Luo Y., Gardiner D.T., Gunasekera R.S., McKeehan W.L., et al. Citrus pectin: characterization and inhibitory effect on fibroblast growth factor-receptor interaction. Journal of Agricultural & Food Chemistry 2001, 49(6):3051-3057.
74. Liu H.Y., Huang Z.L., Yang G.H., Lu W.Q., Yu N.R. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World Journal of Gastroenterology 2008, 14(48):7386-7391.
75. Liu L., Li Y.H., Niu Y.B., Sun Y., Guo Z.J., Li Q., et al. An apple oligogalactan prevents against inflammation and carcinogenesis by targeting LPS/TLR4/NF-κB pathway in a mouse model of colitis-associated colon cancer. Carcinogenesis 2010, 31(10):1822-1832.
76. Louis P., Hold G.L., Flint H.J. The gut microbiota, bacterial metabolites and colorectal cancer. Nature Reviews Microbiology 2014, 12(10):661-672.
77. Lu W.Q., Wang F., Liu H.Y. Influence of oxaliplatin combined with LCP on proliferation and apoptosis of colon cancer cell. Chinese Journal of Gastrointestinal Surgery 2013, 16(1):84-89.
78. von Mach T., Carlsson M.C., Straube T., Nilsson U., Leffler H., Jacob R. Ligand binding and complex formation of galectin-3 is modulated by pH variations. Biochemical Journal 2014, 457(1):107-115.
79. Matarrese P., Tinari N., Semeraro M.L., Natoli C., Iacobelli S., Malorni W. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Letter 2000, 473(3):311-315.
80. Maxwell E.G., Belshaw N.J., Waldron K.W., Morris V.J. Pectin - an emerging new bioactive food polysaccharide. Trends in Food Science & Technology 2012, 24(2):64-73.
81. Mazurek N., Byrd J.C., Sun Y., Hafley M., Ramirez K., Burks J., et al. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death & Differentiation 2012, 19(3):523-533.
82. McCarty M.F., Block K.I. Toward a core nutraceutical program for cancer management. Integrative Cancer Therapies 2006, 5(2):150-171.
83. Mohnen D. Pectin structure and biosynthesis. Current Opinion in Plant Biology 2008, 11(3):266-277.
84. Morris V.J., Belshaw N.J., Waldron K.W., Maxwell E.G. The bioactivity of modified pectin fragments. Bioactive Carbohydrates & Dietary Fibre 2013, 1(1):21-37.
85. Morris V.J., Gromer A., Kirby A.R., Bongaerts R.J.M., Gunning A.P. Using AFM and force spectroscopy to determine pectin structure and (bio) functionality. Food Hydrocolloids 2011, 25(2):230-237.
86. Mossine V.V., Glinsky V.V., Mawhinney T.P. Food-related carbohydrate ligands for galectins. Galectin 2008, 235-270. John Wiley, New Jersey. A.A. Klyosov, Z.J. Witczak, D. Platt (Eds.).
87. Munarin F., Tanzi M.C., Petrini P. Advances in biomedical applications of pectin gels. International Journal of Biological Macromolecules 2012, 51(4):681-689.
88. Nakahara S., Raz A. Biological modulation by lectins and their ligands in tumor progression and metastasis. Anti-Cancer Agents in Medicinal Chemistry 2008, 8(1):22-36.
89. Nangia-Makker P., Hogan V., Honjo Y., Baccarini S., Tait L., Bresalier R., et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. Journal of the National Cancer Institute 2002, 94(24):1854-1862.
90. Newlaczyl A.U., Yu L.G. Galectin-3-A jack-of-all-trades in cancer. Cancer Letters 2011, 313(2):123-128.
91. Ohkami H., Tazawa K., Yamashita I., Shimizu T., Murai K., Kobashi K., et al. Effects of apple pectin on fecal bacterial enzymes in azoxymethane-induced rat colon carcinogenesis. Japanese Journal of Cancer Research 1995, 86(6):523-529.
92. Ohno K., Narushima S., Takeuchi S., Itoh K., Mitsuoka T., Nakayama H., et al. Inhibitory effect of apple pectin and culture condensate of Bifidobacterium longum on colorectal tumors induced by 1,2-dimethylhydrazine in transgenic mice harboring human prototype c-Ha-ras genes. Experimental Animals 2000, 49(4):305-307.
93. Olano-Martin E., Gibson G.R., Rastell R.A. Comparison of the invitro bifidogenic properties of pectins and pectic-oligosaccharides. Journal of Applied Microbiology 2002, 93:505-511.
94. Ozment T.R., Goldman M.P., Kalbfleisch J.H., Williams D.L. Soluble glucan is internalized and trafficked to the Golgi apparatus in macrophages via a clathrin-mediated, lipid raft-regulated mechanism. Journal of Pharmacology & Experimental Therapeutics 2012, 342(3):808-815.
95. Pazur J.H., Erikson M.S., Tay M.E., Allen P.Z. Isomeric, anti-rhamnose antibodies having specificity for rhamnose-containing, streptococcal heteroglycans. Carbohydrate Research 1983, 124(2):253-263.
96. Peng W., Wang H.Y., Miyahara Y., Peng G., Wang R.F. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Research 2008, 68(17):7228-7236.
97. Pienta K.J., Naik H., Akhtar A., Yamazaki K., Replogle T.S., Lehr J., et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. Journal of the National Cancer Institute 1995, 87(5):348-353.
98. Pieters R.J. Inhibition and detection of galectins. Chembiochem 2006, 7(5):721-728.
99. Platt D., Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. Journal of the National Cancer Institute 1992, 84(6):438-442.
100. Puga A.M., Lima A.C., Mano J.F., Concheiro A., Alvarez-Lorenzo C. Pectin-coated chitosan microgels crosslinked on superhydrophobic surfaces for 5-fluorouracil encapsulation. Carbohydrate Polymers 2013, 98(1):331-340.
101. Radosavljevic G., Volarevic V., Jovanovic I., Milovanovic M., Pejnovic N., Arsenijevic N., et al. The roles of Galectin-3 in autoimmunity and tumor progression. Immunologic Research 2012, 52(1-2):100-110.
102. Ramachandran C., Wilk B.J., Hotchkiss A., Chau H., Eliaz I., Melnick S.J. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complementary & Alternative Medicine 2011, 11:59-68.
103. Rao C.V., Chou D., Simi B., Ku H., Reddy B.S. Prevention of colonic aberrant crypt foci and modulation of large bowel microbial activity by dietary coffee fiber, inulin and pectin. Carcinogenesis 1998, 19(10):1815-1819.
104. Salman H., Bergman M., Djaldetti M., Orlin J., Bessler H. Citrus pectin affects cytokine production by human peripheral blood mononuclear cells. Biomedicine & Pharmacotherapy 2008, 62(9):579-582.
105. Sathisha U.V., Jayaram S., Harish Nayaka M.A., Dharmesh S.M. Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources. Glycoconjugate Journal 2007, 24(8):497-507.
106. Schmidgall J., Hensel A. Bioadhesive properties of polygalacturonides against colonic epithelial membranes. International Journal of Biological Macromolecules 2002, 30(5):217-225.
107. Seetharaman J., Kanigsberg A., Slaaby R., Leffler H., Barondes S.H., Rini J.M. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. Journal of Biological Chemistry 1998, 273(21):13047-13052.
108. Shah M.S., Schwartz S.L., Zhao C., Davidson L.A., Zhou B., Lupton J.R., et al. Integrated microRNA and mRNA expression profiling in a rat colon carcinogenesis model: effect of a chemo-protective diet. Physiological Genomics 2011, 43(10):640-654.
109. Song S., Byrd J.C., Mazurek N., Liu K., Koo J.S., Bresalier R.S. Galectin-3 modulates MUC2 mucin expression in human colon cancer cells at the level of transcription via AP-1activation. Gastroenterology 2005, 129(5):1581-1591.
110. Song S., Ji B., Ramachandran V., Wang H., Hafley M., Logsdon C., et al. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One 2012, 7(8):e42699.
111. Straube T., von Mach T., Hönig E., Greb C., Schneider D., Jacob R. pH-dependent recycling of galectin-3 at the apical membrane of epithelial cells. Traffic 2013, 14(9):1014-1027.
112. Streetly M.J., Maharaj L., Joel S., Schey S.A., Gribben J.G., Cotter F.E. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 2010, 115(19):3939-3948.
113. Takei T., Sato M., Ijima H., Kawakami K. In situ gellable oxidized citrus pectin for localized delivery of anticancer drugs and prevention of homotypic cancer cell aggregation. Biomacromolecules 2010, 11(12):3525-3530.
114. Tang X.H., Xie P., Ding Y., Chu L.Y., Hou J.P., Yang J.L., et al. Synthesis, characterization, and invitro and invivo evaluation of a novel pectin-adriamycin conjugate. Bioorganic & Medicinal Chemistry 2010, 18(4):1599-1609.
115. Thibault J.-F., Renard C.M.G.C., Axelos M.A.V., Roger P., Crepeau M.-J. Studies of the length of homogalacturonic regions in pectins by acid hydrolysis. Carbohydrate Research 1993, 238:271-286.
116. Umar S., Morris A.P., Kourouma F., Sellin J.H. Dietary pectin and calcium inhibit colonic proliferation invivo by differing mechanisms. Cell Proliferation 2003, 36(6):361-375.
117. Urias-Orona V., Huerta-Oros J., Carvajal-Millán E., Lizardi-Mendoza J., Rascón-Chu A., Gardea A.A. Component analysis and free radicals scavenging activity of Cicer arietinum L. husk pectin. Molecules 2010, 15(10):6948-6955.
118. Vayssade M., Sengkhamparn N., Verhoef R., Delaigue C., Goundiam O., Vigneron P., et al. Antiproliferative and proapoptotic actions of okra pectin on B16F10 melanoma cells. Phytotherapy Research 2010, 24(7):982-989.
119. Wai W.W., AlKarkhi A.F.M., Easa A.M. Comparing biosorbent ability of modified citrus and durian rind pectin. Carbohydrate Polymers 2010, 79(3):584-589.
120. Wang Y., Balan V., Kho D., Hogan V., Nangia-Makker P., Raz A. Galectin-3 regulates p21 stability in human prostate cancer cells. Oncogene 2013, 32(42):5058-5065.
121. Wang X.S., Dong Q., Zuo J.P., Fang J.N. Immunological activities and structure of pectin from. Centella asiatica. Carbohydrate Research 2003, 338(22):2393-2402.
122. Wang F., Liu H.Y. Inhibitory effect of combined treatment with oxaliplatin and low molecular weight citrus pectin on proliferation of HCT116 cells and its mechanism. Chines Journal of General Surgery 2011, 20(10):1053-1057.
123. Weigel P.H., Yik J.H. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochimica et Biophysica Acta 2002, 1572(2-3):341-363.
124. Wicker L., Kim Y., Kim M.J., Thirkield B., Lin Z., Jung J. Pectin as a bioactive polysaccharide - extracting tailored function from less. Food Hydrocolloids 2014, 42(2):251-259.
125. Wittmann V., Pieters R.J. Bridging lectin binding sites by multivalent carbohydrates. Chemical Society Reviews 2013, 42(10):4492-4503.
126. Wong T.W., Colombo G., Sonvico F. Pectin matrix as oral drug delivery vehicle for colon cancer treatment. AAPS PharmSciTech 2011, 12(1):201-214.
127. Xue J., Gao X., Fu C., Cong Z., Jiang H., Wang W., et al. Regulation of galectin-3-induced apoptosis of Jurkat cells by both O-glycans and N-glycans on CD45. FEBS Letter 2013, 587(24):3986-3994.
128. Yang C., Gou Y., Chen J., An J., Chen W., Hu F. Structural characterization and antitumor activity of a pectic polysaccharide from. Codonopsis pilosula. Carbohydrate Polymers 2013, 98(1):886-895.
129. Yan J., Katz A. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgendependent and -independent prostate cancer cells. Integrative Cancer Therapies 2010, 9(2):197-203.
130. Yapo B.M., Lerouge P., Thibault J.-F., Ralet M.-C. Pectins from citrus peel cell walls contain homogalacturonans homogenous with respect to molar mass, rhamnogalacturonan I and rhamnogalacturonan II. Carbohydrate Polymers 2007, 69(3):426-435.
131. Yoshii T., Fukumori T., Honjo Y., Inohara H., Kim H.R., Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. Journal of Biological Chemistry 2002, 277(9):6852-6857.
132. Yu C.Y., Wang Y.M., Li N.M., Liu G.S., Yang S., Tang G.T., et al. Invitro and invivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy. Molecular Pharmaceutics 2014, 11(2):638-644.
133. Zhang D., Li Y.H., Mi M., Jiang F.L., Yue Z.G., Sun Y., et al. Modified apple polysaccharides suppress the migration and invasion of colorectal cancer cells induced by lipopolysaccharide. Nutrition Research 2013, 33(10):839-848.
134. Zhang W.B. MCP polysaccharide: Preparation, analysis and its anti-tumor activity 2006, Ph. D. thesis, Tianjin University, Tianjin.
135. Zhang W.B. Progress in galectin-3 and its inhibitor. Chinese Pharmaceutical Journal 2009, 44(3):165-169.
136. Zhang W.B., Gao L., Shi X.F., Zhang Q.L. Determination of the molecular mass of modified citrus pectin using high performance size exclusion chromatography. Chinese Journal of Chromatography 2007, 25(5):711-714.
137. Zhang W.B., Liu C.Z., Gao L. Modified citrus pectin: preparation, characterization and anti-cancer activities. Chemical Journal of Chinese Universities 2010, 31(5):964-969.
138. Zhang W.B., Xu P., Gao L., Yan Q.H., Yang W.M. Preparation and antitumor application of modified pectinwithhigh bioavailability 2013, Chinese patent, ZL. 201110200381.4.
139. Zhang X., Li S., Sun L., Ji L., Zhu J., Fan Y., et al. Further analysis of the structure and immunological activity of an RG-I type pectin from. Panax ginseng. Carbohydrate Polymers 2012, 89(2):519-525.
140. Zhang Y.Y., Mu T.T., Zhang M. Effects of modified sweet potato pectins on the proliferation of Cancer cells. Scientia Agricultura Sinica 2012, 45(9):1798-1806.
141. Zhao Q., Barclay M., Hilkens J., Guo X., Barrow H., Rhodes J.M., et al. Interaction between circulating galectin-3 andcancer-associated MUC1 enhances tumour cell homotypicaggregation and prevents anoikis. Molecular Cancer 2010, 9:154-166.
142. Zunft H.J., Goldin-Lang P., Dongowski G. DNA adducts in tissues of germ-free and conventional rats fed high- and low-esterified pectins. Cancer Letters 1997, 114(1-2):43-46.